Insulet's Pumps Primed for Growth, but Can It Beat the Competition? Insulet Corporation (NASDAQ:PODD) has been a driving force in the medical device market, particularly in the treatment of diabetes.
The company's recent initiation of coverage by Deutsche Bank analyst Kieran Ryan, with a Buy rating and price target of $190, suggests that Insulet's stock is poised for growth.
Ryan asserts that Insulet remains one of the strongest players in the tubeless insulin pump market due to its Omnipod platform.